Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
17. Oktober 2023 07:00 ET
|
Evelo Biosciences, Inc.
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE)...
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
14. August 2023 07:30 ET
|
Evelo Biosciences, Inc.
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon...
Evelo Biosciences Closes $25.5 Million Private Placement
12. Juli 2023 07:30 ET
|
Evelo Biosciences, Inc.
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE...
Evelo Biosciences Announces $25.5 Million Private Placement
10. Juli 2023 07:30 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered...
Evelo Biosciences Announces Reverse Stock Split Effective
29. Juni 2023 09:00 ET
|
Evelo Biosciences, Inc.
– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 – CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical...
Evelo Biosciences Provides Clinical Updates
26. April 2023 07:30 ET
|
Evelo Biosciences, Inc.
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV...
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
16. März 2023 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally...
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
09. März 2023 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered...
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
01. März 2023 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory...
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
27. Februar 2023 06:00 ET
|
Evelo Biosciences, Inc.
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been...